Back
28 October 2022

Bridging the Gap: How Bracken Supports Biotech and Pharma Companies Using Imaging Endpoints in Clinical Trials

Written by Colin G. Miller

The Scenario

As the use of imaging endpoints in clinical trials has increased steadily over the last 30 years, an imaging core lab (ICL) — or sometimes called an imaging CRO — is often involved.

Sponsors using imaging endpoints in clinical trials are often dependent on ICLs they lack the expertise to oversee. That knowledge gap creates real risk: inadequate oversight of ICLs can lead to data quality failures, protocol misalignment, and costly delays....  

Bracken's imaging experts bridge that gap: protecting data integrity, timelines, and submissions.

RECENT CASE STUDIES

The Data Most Companies Throw Away: How a Reconstruction Workflow Can Help Save a Clinical Trial

The Scenario Most sites discard the richest data a PET scanner produces; list mode data is usually..

Embedding Patient Engagement into Clinical Development

The Scenario A global, mid-sized biopharmaceutical company had made PFDD a strategic priority and..